What is the recommended approach to starting metformin in patients with reduced kidney function?

• A. Do not start metformin if eGFR <45; reduce dose at eGFR 30-44; discontinue if eGFR <30; monitor renal function.
• B. Start metformin regardless of eGFR.
• C. Start at high dose and adjust upward as tolerated.
• D. Metformin should be discontinued only if eGFR <15.

Answer: (A)

Metformin is cleared by the kidneys, so kidney function directly affects how the drug is handled in the body. When eGFR falls, drug exposure rises, which increases the risk of lactic acidosis, a serious complication. That’s why the safest approach uses specific eGFR thresholds to guide whether to start metformin, how to dose it, and when to stop it, with regular monitoring of kidney function.

The recommended plan aligns with these safety steps: do not start metformin if eGFR is below 45; if eGFR is in the 30–44 range, reduce the dose; if eGFR drops below 30, discontinue; and always monitor renal function. This provides a clear framework to balance achieving glucose control with minimizing risks.

Starting metformin regardless of kidney function neglects renal safety. Beginning at a high dose and increasing it while kidney function is reduced exposes the patient to higher drug levels and greater risk. Discontinuing only when eGFR falls below 15 ignores important intermediate stages of impairment where dose adjustments or stopping the drug are warranted.